Market Research Logo

Global Lung Cancer Therapeutics Market – Industry Trends and Forecast to 2026

Global Lung Cancer Therapeutics Market – Industry Trends and Forecast to 2026

Global lung cancer therapeutics market is expected to grow at a healthy CAGR of 12.4% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.
Market Segmentation
By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumors, Mediastinal Tumors, Mesothelioma, Chest Wall Tumors), Molecule Type (Small Molecules, Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Therapy Type (Single Drug Therapy, Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle east & Africa) Industry Trends and Forecast to 2026
Major growing sectors under the market segmentation are as follows:
• On the basis of cancer type, the non-small cell lung cancer is dominating the global lung cancer therapeutics market. Lung cancer is the second most common cancer type including small cell and non-small cell lung cancer. Amongst these 80–85% cases are non-small cell lung cancer. This type of cancer grows and spreads more slowly than small cell lung cancer and therefore it is dominating the market.
• On the basis of molecule type, the small molecule segment is dominating the global lung cancer therapeutics market. The small molecule better effects and progression free survival of lung cancer and these agents also inhibit the growth of the metastatic cell. Due to all these reasons they are more preferred than the other types.
• On the drug class, the alkylating drug segment is dominating the lung cancer therapeutics market. This is the first discovered drug for the treatment of cancer. Alkylating directly damage DNA and prevents the cancer cells cell division. The alkylating agent can be used in every stage of cancer. This drug shows pre and post stage. This drug also shows reduced drug accumulation and the increased detoxification.
• On the basis of treatment type, the chemotherapy segment is dominating the lung cancer therapeutics market. Chemotherapy is a traditional process in which drugs are used to kill or inhibit cancerous cells as it is the most accepted treatment. Whereas, targeted therapy is becoming more familiar in the lung cancer sector as these classes of drugs specifically focuses on specific genetic mutations present in the tumor cells.
• On the basis of therapy type, single drug therapy segment is dominating the lung cancer therapeutics market. The single drug therapy is the first evolved therapy used for the treatment of lung cancer. Single drug therapy is dominating the market as it is mostly preferred for the treatment of old age population, patients with poor performance status and patients who are not able to take the combination therapy. Whereas the combination drug therapy is expected to grow in future as many combination drugs are under clinical trials and are expected to launch soon. Also, few studies have shown that combination drugs can have better results as compared to the single drug therapy which will contribute to the growth of the combination therapy in the forecast period.
• On the basis of end user, hospitals segment is dominating the lung cancer therapeutics market. The hospital segment is dominating in the lung cancer therapeutics because hospitals provides many advantages over the other segments which includes, 24hours supportive care, immediate care for the emergency, availability of physicians, surgeons and medication.
• On the basis of distribution channel, hospital pharmacy segment is dominating the lung cancer therapeutics market. Hospital pharmacy is dominating the global lung cancer therapeutics market as the lung cancer therapy products are prescribed based which is majorly available in hospital pharmacy.
Key Market Players
The key market players for global lung cancer therapeutics market are listed below:
• Takeda Pharmaceutical Company Limited
• ONO PHARMACEUTICAL CO., LTD.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Eli Lilly and Company.
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• CELGENE CORPORATION
• AMGEN INC.
• Sanofi
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd.
• ALLERGAN
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Astellas Pharma Inc.
• Sumitomo Dainippon Pharma Co., Ltd
• Others

The single user license is non-downloadable and non-printable. Global Site license allows these actions.


1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of Global Lung Cancer Therapeutics Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Currency And Pricing
2.5 Research Methodology
2.6 Primary Interviews With Key Opinion Leaders
2.7 Dbmr Market Position Grid
2.8 Dbmr Market Challenge Matrix
2.9 Dbmr Vendor Share Analysis
2.10 Multivariate Modelling
2.11 Product Time Line
2.12 Secondary Sources
2.13 Assumptions
3 Market Overview
3.1 Drivers
3.1.1 Increasing Cases Of Lung Cancer
3.1.2 Growing Number Of Smokers
3.1.3 Government / Organizations Funding For The R&D Of New Drugs
3.1.4 Increasing Awareness
3.1.5 Strategic Initiatives Of The Companies
3.2 Restrains
3.2.1 Pricing Pressure
3.2.2 High Cost
3.3 Opportunities
3.3.1 Approvals And Product Pipepline
3.3.2 Health Tourism
3.3.3 New Product Launches
3.4 Challenges
3.4.1 Side Effects
3.4.2 Lack Of Number Of Oncologists
3.4.3 Unmet Medical Needs
4 Executive Summary
5 Premium Insights
6 Epidemiology Of Lung Cancer
7 Regulatory Procedure
8 Pipeline Drugs
9 Global Lung Cancer Therapeutics Market, By Cancer Type
9.1 Overview
9.2 Non-small Cell Lung Cancer
9.2.1 Squamous Cell Carcinoma
9.2.2 Pulmonary Adenocarcinoma
9.2.3 Adenosquamous Carcinoma (Asc)
9.2.4 Large Cell Carcinoma
9.2.5 Sarcomatoid Carcinoma
9.2.6 Undifferentiated Non-small Cell Lung Cancer
9.2.7 Salivary Gland-type Lung Carcinoma
9.2.7.1 Adenoid Cystic Carcinoma
9.2.7.2 Mucoepidermoid Carcinoma
9.2.7.3 Acinic Cell Carcinoma
9.2.7.4 Epithelial-myoepithelial Carcinoma
9.2.7.5 Granular Cell Lung Tumors
9.3 Metastatic Lung Cancer
9.4 Mesothelioma
9.5 Chest Wall Tumors
9.5.1 Primary Tumors
9.5.2 Metastatic Tumors
9.5.3 Sarcomas
9.6 Pulmonary Neuroendocrine Tumors
9.6.1 Carcinoid Tumors
9.6.1.1 Typical Carcinoid Tumors
9.6.1.2 Atypical Carcinoid Tumors
9.6.2 Large Cell Neuroendocrine Lungs Carcinoma
9.6.3 Small-cell Lung Cancer
9.6.3.1 Small Cell Carcinoma
9.6.3.2 Combined Small Cell Carcinoma
9.7 Mediastinal Tumors
9.7.1 Germ Cell Tumors
9.7.2 Lymphomas
9.7.3 Thymomas
10 Global Lung Cancer Therapeutics Market, By Molecule Type
10.1 Overview
10.2 Small Molecule
10.3 Bilogics
11 Global Lung Cancer Therapeutics Market, By Drug Class
11.1 Overview
11.2 Alkylating Agents
11.3 Antimetabolites
11.4 Mitotic Inhibitors
11.5 Multikinase Inhibitors
11.6 Egfr Inhibitors
11.7 Others
12 Global Lung Cancer Therapeutics Market, By Treatment Type
12.1 Overview
12.2 Radiation Therapy
12.2.1 External Beam
12.2.2 Brachytherapy (Internal Or Implant Radiation Therapy)
12.2.3 Stereotactic Body Radiation Therapy (Sbrt) / Stereotactic Ablative Radiotherapy (Sabr)
12.2.4 Stereotactic Radiosurgery (Srs)
12.3 Chemotherapy
12.3.1 Cisplatin
12.3.2 Paclitaxel (Taxol)
12.3.3 Vinorelbine (Navelbine)
12.3.4 Docetaxel (Taxotere)
12.3.5 Alimta
12.3.6 Gemcitabine (Gemzar)
12.3.7 Durvalumab (Imfinzi)
12.3.8 Others
12.4 Targeted Therapy
12.4.1 Epidermal Growth Factor Receptor (Egfr) Inhibitors
12.4.2 Anaplastic Lymphoma Kinase (Alk) Inhibitors
12.4.3 Anti-angiogenesis Therapy
12.4.4 Monoclonal Antibodies
12.4.5 Others
12.5 Immunotherapy
12.5.1 Atezolizumab (Tecentriq)
12.5.2 Durvalumab (Imfinzi)
12.5.3 Nivolumab (Opdivo)
12.5.4 Pembrolizumab (Keytruda)
12.6 Others
13 Global Lung Cancer Therapeutics Market, By Therapy Type
13.1 Overview
13.2 Single Drug Therapy
13.3 Combination Therapy
14 Global Lung Cancer Therapeutics Market, By End User
14.1 Overview
14.2 Hospitals
14.3 Specialty Clinics
14.4 Homecare
14.5 Others
15 Global Lung Cancer Therapeutics Market, By Distribution Channel
15.1 Overview
15.2 Hospital Pharmacy
15.3 Retail Pharmacy
15.4 Online
15.5 Others
16 Global Lung Cancer Therapeutics Market, By Geography
16.1 Overview
16.2 North America
16.2.1 U.S.
16.2.2 Canada
16.2.3 Mexico
16.3 Europe
16.3.1 Germany
16.3.2 France
16.3.3 U.K.
16.3.4 Italy
16.3.5 Spain
16.3.6 Switzerland
16.3.7 Netherlands
16.3.8 Belgium
16.3.9 Russia
16.3.10 Turkey
16.3.11 Rest Of Europe
16.4 Asia-pacific
16.4.1 Japan
16.4.2 China
16.4.3 India
16.4.4 Australia
16.4.5 South Korea
16.4.6 Indonesia
16.4.7 Thailand
16.4.8 Malaysia
16.4.9 Singapore
16.4.10 Philippines
16.4.11 Rest Of Asia-pacific
16.5 South America
16.5.1 Brazil
16.5.2 Rest Of South America
16.6 Middle East And Africa
16.6.1 South Africa
16.6.2 Rest Of Middle East And Africa
17 Global Lung Cancer Therapeutics Market, Company Landscape
17.1 Company Share Analysis: Global
17.2 Company Share Analysis: North America
17.3 Company Share Analysis: Europe
17.4 Company Share Analysis: Asia-pacific
18 Company Profiles
18.1 F. Hoffmann-la Roche Ltd
18.1.1 Company Snapshot
18.1.2 Revenue Analysis
18.1.3 Geographical Presence
18.1.4 Company Share Analysis
18.1.5 Product Portfolio
18.1.6 Recent Developments
18.2 Merck & Co., Inc.
18.2.1 Company Overview
18.2.2 Revenue Analysis
18.2.3 Geographical Presence
18.2.4 Company Share Analysis
18.2.5 Product Portfolio
18.2.6 Recent Developments
18.3 Bristol-myers Squibb Company
18.3.1 Company Overview
18.3.2 Revenue Analysis
18.3.3 Geographical Presence
18.3.4 Company Share Analysis
18.3.5 Product Portfolio
18.3.6 Recent Developments
18.4 Astrazeneca
18.4.1 Company Snapshot
18.4.2 Revenue Analysis
18.4.3 Geographical Presence
18.4.4 Company Share Analysis
18.4.5 Product Portfolio
18.4.6 Recent Developments
18.5 Eli Lilly And Company
18.5.1 Company Snapshot
18.5.2 Revenue Analysis
18.5.3 Geographical Presence
18.5.4 Company Share Analysis
18.5.5 Product Portfolio
18.5.6 Recent Developments
18.6 Allergan
18.6.1 Company Overview
18.6.2 Revenue Analysis
18.6.3 Geographical Presence
18.6.4 Product Portfolio
18.6.5 Recent Developments
18.7 Amgen Inc.
18.7.1 Company Overview
18.7.2 Revenue Analysis
18.7.3 Geographical Presence
18.7.4 Product Portfolio
18.7.5 Recent Developments
18.8 Astellas Pharma Inc.
18.8.1 Company Overview
18.8.2 Revenue Analysis
18.8.3 Geographical Presence
18.8.4 Product Portfolio
18.8.5 Recent Developments
18.9 Boehringer Ingelheim International Gmbh
18.9.1 Company Overview
18.9.2 Revenue Analysis
18.9.3 Geographical Presence
18.9.4 Product Portfolio
18.9.5 Recent Developments
18.10 Celgene Corporation
18.10.1 Company Overview
18.10.2 Revenue Analysis
18.10.3 Geographical Presence
18.10.4 Product Portfolio
18.10.5 Recent Developments
18.11 Dr. Reddy’s Laboratories Ltd.
18.11.1 Company Snapshot
18.11.2 Revenue Analysis
18.11.3 Geographical Presence
18.11.4 Product Portfolio
18.11.5 Recent Developments
18.12 Glaxosmithkline Plc.
18.12.1 Company Overview
18.12.2 Revenue Analysis
18.12.3 Geographical Presence
18.12.4 Product Portfolio
18.12.5 Recent Developments
18.13 Johnson & Johnson Services, Inc.
18.13.1 Company Snapshot
18.13.2 Revenue Analysis
18.13.3 Geographical Presence
18.13.4 Product Portfolio
18.13.5 Recent Developments
18.14 Novartis Ag
18.14.1 Company Snapshot
18.14.2 Revenue Analysis
18.14.3 Geographical Presence
18.14.4 Product Portfolio
18.14.5 Recent Development
18.15 Ono Pharmaceutical Co., Ltd.
18.15.1 Company Overview
18.15.2 Revenue Analysis
18.15.3 Geographical Presence
18.15.4 Product Portfolio
18.15.5 Recent Developments
18.16 Pfizer Inc.
18.16.1 Company Snapshot
18.16.2 Recent Financials
18.16.3 Geographical Presence
18.16.4 Product Portfolio
18.16.5 Recent Developments
18.17 Sanofi
18.17.1 Company Overview
18.17.2 Revenue Analysis
18.17.3 Geographical Presence
18.17.4 Product Portfolio
18.17.5 Recent Developments
18.18 Sumitomo Dainippon Pharma Co., Ltd.
18.18.1 Company Overview
18.18.2 Revenue Analysis
18.18.3 Geographical Presence
18.18.4 Product Portfolio
18.18.5 Recent Developments
18.19 Sun Pharmaceutical Industries Ltd.
18.19.1 Company Snapshot
18.19.2 Revenue Analysis
18.19.3 Geographical Presence
18.19.4 Product Portfolio
18.19.5 Recent Developments
18.20 Takeda Pharmaceutical Company Limited
18.20.1 Company Overview
18.20.2 Revenue Analysis
18.20.3 Geographical Presence
18.20.4 Product Portfolio
18.20.5 Recent Developments
18.21 Teva Pharmaceutical Industries Ltd.
18.21.1 Company Overview
18.21.2 Revenue Analysis
18.21.3 Geographical Presence
18.21.4 Product Portfolio
18.21.5 Recent Developments
19 Questionnaire
20 Related Reports
List Of Figures
Figure 1 Global Lung Cancer Therapeutics Market: Segmentation
Figure 2 Global Lung Cancer Therapeutics Market: Data Validation Model
Figure 3 Global Lung Cancer Therapeutics Market: Droc Analysis
Figure 4 Global Lung Cancer Therapeutics Market: Global Vs Regional Market Analysis
Figure 5 Global Lung Cancer Therapeutics Market: Company Research Analysis
Figure 6 Global Lung Cancer Therapeutics Market: Interview Demographics
Figure 7 Global Lung Cancer Therapeutics Market: Dbmr Market Position Grid
Figure 8 Global Lung Cancer Therapeutics Market: The Market Challenge Matrix
Figure 9 Global Lung Cancer Therapeutics Market: Dbmr Vendor Share Analysis
Figure 10 Drivers, Restraints, Opportunities And Challenges Of Global Lung Cancer Therapeutics Market
Figure 11 Country Wise Lung Cancer Rates In 2018
Figure 12 Global Lung Cancer Therapeutics Market: Segmentation
Figure 13 North America Is Anticipated To Dominate The Lung Cancer Therapeutics Market And Asia-pacific Is Estimated To Be Increasing With The Highest Cagr In The Forecast Period From 2019 To 2026
Figure 14 Increasing Cases Of Lung Cancer, Growing Number Of Smokers And Rising Government Initiatives Are Expected To Drive The Global Lung Cancer Therapeutics Market In The Forecast Period 2019 To 2026
Figure 15 Non-small Cell Lung Cancer Is Expected To Account For The Largest Share Of The Global Lung Cancer Therapeutics Market In 2019 & 2026
Figure 16 Asia-pacific Is The Maximum Growing And Most Profitable Revenue Pockets For Global Lung Cancer Therapeutics Market In The Forecast Period From 2019 To 2026
Figure 17 Worldwide Lung Cancer Incidence (2018)
Figure 18 Worldwide Prevalence Of Lung Cancer For Last 5 Years
Figure 19 Worldwide Mortality Rate Of Lung Cancer (2018)
Figure 20 Global Lung Cancer Therapeutics Market: By Cancer Type, 2018
Figure 21 Global Lung Cancer Therapeutics Market: By Molecule Type, 2018
Figure 22 Global Lung Cancer Therapeutics Market: By Drug Class, 2018
Figure 23 Global Lung Cancer Therapeutics Market: By Treatment Type, 2018
Figure 24 Global Lung Cancer Therapeutics Market: By Therapy Type, 2018
Figure 25 Global Lung Cancer Therapeutics Market: By End User, 2018
Figure 26 Global Lung Cancer Therapeutics Market: By Distribution Channel, 2018
Figure 27 Global Lung Cancer Therapeutics Market: Snapshot (2018)
Figure 28 Global Lung Cancer Therapeutics Market: By Geography (2018)
Figure 29 Global Lung Cancer Therapeutics Market: By Geography (2019 & 2026)
Figure 30 Global Lung Cancer Therapeutics Market: By Geography (2018 & 2026)
Figure 31 Global Lung Cancer Therapeutics Market: By Cancer Type (2019-2026)
Figure 32 North America Lung Cancer Therapeutics Market: Snapshot (2018)
Figure 33 North America Lung Cancer Therapeutics Market: By Country (2018)
Figure 34 North America Lung Cancer Therapeutics Market: By Country (2019 & 2026)
Figure 35 North America Lung Cancer Therapeutics Market: By Country (2018 & 2026)
Figure 36 North America Lung Cancer Therapeutics Market: By Cancer Type (2019-2026)
Figure 37 Europe Lung Cancer Therapeutics Market: Snapshot (2018)
Figure 38 Europe Lung Cancer Therapeutics Market: By Country (2018)
Figure 39 Europe Lung Cancer Therapeutics Market: By Country (2019 & 2026)
Figure 40 Europe Lung Cancer Therapeutics Market: By Country (2018 & 2026)
Figure 41 Europe Lung Cancer Therapeutics Market: By Cancer Type (2019-2026)
Figure 42 Asia-pacific Lung Cancer Therapeutics Market: Snapshot (2018)
Figure 43 Asia-pacific Lung Cancer Therapeutics Market: By Country (2018)
Figure 44 Asia-pacific Lung Cancer Therapeutics Market: By Country (2019 & 2026)
Figure 45 Asia-pacific Lung Cancer Therapeutics Market: By Country (2018 & 2026)
Figure 46 Asia-pacific Lung Cancer Therapeutics Market: By Cancer Type (2019-2026)
Figure 47 South America Lung Cancer Therapeutics Market: Snapshot (2018)
Figure 48 South America Lung Cancer Therapeutics Market: By Country (2018)
Figure 49 South America Lung Cancer Therapeutics Market: By Country (2019 & 2026)
Figure 50 South America Lung Cancer Therapeutics Market: By Country (2018 & 2026)
Figure 51 South America Lung Cancer Therapeutics Market: By Cancer Type (2019-2026)
Figure 52 Middle East & Africa Lung Cancer Therapeutics Market: Snapshot (2018)
Figure 53 Middle East & Africa Lung Cancer Therapeutics Market: By Country (2018)
Figure 54 Middle East & Africa Lung Cancer Therapeutics Market: By Country (2019 & 2026)
Figure 55 Middle East & Africa Lung Cancer Therapeutics Market: By Country (2018 & 2026)
Figure 56 Middle East & Africa Lung Cancer Therapeutics Market: By Cancer Type (2019-2026)
Figure 57 Global Lung Cancer Therapeutics Market: Company Share 2018 (%)
Figure 58 North America Lung Cancer Therapeutics Market: Company Share 2018 (%)
Figure 59 Europe Lung Cancer Therapeutics Market: Company Share 2018 (%)
Figure 60 Asia-pacific Lung Cancer Therapeutics Market: Company Share 2018 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report